Trinity Biotech (NASDAQ:TRIB) Now Covered by Analysts at

Analysts at started coverage on shares of Trinity Biotech (NASDAQ:TRIBGet Rating) in a note issued to investors on Wednesday. The brokerage set a “buy” rating on the stock.

Trinity Biotech Stock Down 4.2 %

Trinity Biotech stock opened at $0.92 on Wednesday. The company has a 50 day moving average of $0.95 and a 200-day moving average of $1.07. The company has a quick ratio of 1.39, a current ratio of 2.69 and a debt-to-equity ratio of 8.70. Trinity Biotech has a twelve month low of $0.80 and a twelve month high of $1.50. The stock has a market capitalization of $35.06 million, a PE ratio of -0.71 and a beta of 1.41.

Trinity Biotech (NASDAQ:TRIBGet Rating) last announced its earnings results on Thursday, March 23rd. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.12). Trinity Biotech had a negative return on equity of 724.07% and a negative net margin of 54.84%. The company had revenue of $18.04 million during the quarter, compared to analyst estimates of $18.00 million. On average, equities research analysts anticipate that Trinity Biotech will post -0.22 EPS for the current fiscal year.

Institutional Investors Weigh In On Trinity Biotech

Institutional investors have recently bought and sold shares of the company. Atria Wealth Solutions Inc. bought a new position in shares of Trinity Biotech during the 1st quarter worth approximately $27,000. Virtu Financial LLC bought a new position in Trinity Biotech in the first quarter valued at approximately $40,000. Whitefort Capital Management LP grew its stake in Trinity Biotech by 1,067.8% in the first quarter. Whitefort Capital Management LP now owns 409,517 shares of the company’s stock valued at $434,000 after purchasing an additional 374,449 shares in the last quarter. Hunter Associates Investment Management LLC increased its position in shares of Trinity Biotech by 1.5% during the 4th quarter. Hunter Associates Investment Management LLC now owns 1,823,633 shares of the company’s stock worth $1,809,000 after purchasing an additional 26,443 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in shares of Trinity Biotech by 2.4% in the 2nd quarter. Renaissance Technologies LLC now owns 1,503,336 shares of the company’s stock valued at $1,842,000 after buying an additional 34,900 shares during the last quarter. Institutional investors own 18.41% of the company’s stock.

Trinity Biotech Company Profile

(Get Rating)

Trinity Biotech Plc engages in the development, manufacture, and marketing of medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market. It operates through the Americas and Rest of World geographical segments. The company was founded by Ronan O’Caoimh and Denis R.

Featured Articles

Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with's FREE daily email newsletter.